NewAmsterdam Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:KH6 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
30 Dec 24	Sell€411,963	Forbion Capital Partners B.V.	Company	16,738	€24.61
27 Dec 24	Sell€1,046,407	Forbion Capital Partners B.V.	Company	42,009	€24.94
24 Dec 24	Sell€1,257,407	Forbion Capital Partners B.V.	Company	51,071	€25.15
19 Dec 24	Sell€2,196,716	Forbion Capital Partners B.V.	Company	88,178	€25.57
16 Dec 24	Sell€26,085	Forbion Capital Partners B.V.	Company	1,096	€23.80
13 Dec 24	Buy€81,218,096	Frazier Life Sciences Management, LP	Company	3,689,475	€23.34
13 Dec 24	Sell€2,521,898	Forbion Capital Partners B.V.	Company	104,409	€24.94
13 Dec 24	Sell€347,388	Forbion Capital Partners B.V.	Company	14,441	€24.06
11 Dec 24	Sell€6,279,315	Forbion Capital Partners B.V.	Company	259,252	€25.85
18 Nov 24	Sell€555,972	Forbion Capital Partners B.V.	Company	23,443	€23.73
14 Nov 24	Sell€246,516	Forbion Capital Partners B.V.	Company	10,430	€23.64
26 Sep 24	Buy€15,508	Juliette Audet	Individual	1,104	€14.05
20 Aug 24	Buy€73,272	Michael Davidson	Individual	5,000	€14.65
20 Jun 24	Buy€80,543	Michael Davidson	Individual	5,000	€16.11
26 Mar 24	Buy€167,396	Frazier Life Sciences Management, LP	Company	8,429	€19.86
13 Feb 24	Buy€88,626	Louis Lange	Individual	5,000	€17.73

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KH6?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	874,545	0.817%
Hedge Funds	8,024,565	7.5%
General Public	17,913,474	16.7%
Institutions	35,130,132	32.8%
VC/PE Firms	45,110,503	42.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 30%.

Top Shareholders

Top 25 shareholders own 76.7% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.9%	Frazier Life Sciences Management, LP	15,916,418	€317.8m	23.8%	14.09%
9.95%	Forbion Capital Partners B.V.	10,656,172	€212.8m	-9.93%	48.9%
9.78%	Bain Capital Life Sciences Investors, LLC	10,473,913	€209.2m	0%	29.42%
7.53%	RA Capital Management, L.P.	8,064,000	€161.0m	0%	2.42%
7.5%	Viking Global Investors LP	8,024,565	€160.2m	0%	0.61%
3.79%	The Morningside Group Limited	4,060,923	€81.1m	0%	6.62%
3.74%	Jennison Associates LLC	3,998,541	€79.8m	292%	0.05%
2.68%	Medicxi Ventures (UK) LLP	2,869,565	€57.3m	0%	13.19%
2.31%	Cormorant Asset Management, LP	2,470,000	€49.3m	7.39%	3.32%
1.44%	Janus Henderson Group plc	1,540,729	€30.8m	51.1%	0.01%
1.42%	BVF Partners L.P.	1,521,948	€30.4m	0%	1.17%
1.41%	Polar Capital Holdings Plc	1,505,000	€30.1m	50.1%	0.12%
1.29%	Adage Capital Management, L.P.	1,380,000	€27.6m	-9.8%	0.05%
1.09%	Woodline Partners LP	1,164,677	€23.3m	141%	0.23%
0.95%	Pictet Asset Management Limited	1,016,847	€20.3m	48.7%	0.02%
0.86%	Artal Group S.A.	920,564	€18.4m	15.1%	0.63%
0.84%	Deerfield Management Company, L.P. Series C	901,750	€18.0m	3.74%	0.36%
0.83%	Avidity Partners Management, L.P.	889,700	€17.8m	59.1%	1.13%
0.77%	AllianceBernstein L.P.	829,189	€16.6m	0%	0.01%
0.77%	GMT Capital Corp.	829,036	€16.6m	-7.04%	0.54%
0.76%	Michael Davidson	818,563	€16.3m	0.61%	no data
0.63%	Medical Strategy GmbH, Asset Management Arm	671,177	€13.4m	0%	0.9%
0.55%	Decheng Capital LLC	590,000	€11.8m	47.5%	3.7%
0.49%	Citadel Advisors LLC	522,465	€10.4m	144%	0.01%
0.44%	Affinity Asset Advisors, LLC	472,390	€9.4m	11.6%	1.96%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/30 08:50
End of Day Share Price	2025/01/30 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Judah Frommer	Credit Suisse
Debjit Chattopadhyay	Guggenheim Securities, LLC
Antonio Arce	H.C. Wainwright & Co.